TABLE 3.

Comparison of results of individual HPV genotype detection in samples collected in liquid-based medium and solid carrier devices among CVT participants^a

HPV type	No. of samples				% Positive		Agreement		Kappa (95% CI)	Pb
	PC+/FTA+	PC−/FTA+	PC+/FTA−	PC−/FTA−	FTA	PC	Overall	Among positives
6	4	2	0	313	1.9	1.3	0.99	0.67	0.80 (0.52–1.0)	0.500
11	2	1	0	316	0.9	0.6	1.00	0.67	0.80 (0.41–1.0)	1.000
16	17	4	1	297	6.6	5.6	0.98	0.77	0.86 (0.75–0.98)	0.375
18	4	1	1	313	1.6	1.6	0.99	0.67	0.80 (0.52–1.0)	1.000
31	5	4	2	308	2.8	2.2	0.98	0.45	0.62 (0.33–0.90)	0.686
33	0	2	1	316	0.6	0.3	0.99	0.00	0.00 (−0.01–0.00)	1.000
34	1	2	1	315	0.9	0.6	0.99	0.25	0.40 (−0.15–0.94)	1.000
35	6	2	0	311	2.5	1.9	0.99	0.75	0.85 (0.65–1.0)	0.500
39	4	3	1	311	2.2	1.6	0.99	0.50	0.66 (0.35–0.97)	0.625
40	2	2	1	314	1.3	0.9	0.99	0.40	0.57 (0.13–1.0)	1.000
42	1	1	0	317	0.6	0.3	1.00	0.50	0.67 (0.05–1.0)	1.000
43	3	1	1	314	1.3	1.3	0.99	0.60	0.75 (0.41–1.0)	1.000
44	4	4	0	311	2.5	1.3	0.99	0.50	0.66 (0.35–0.97)	0.125
45	1	2	1	315	0.9	0.6	0.99	0.25	0.40 (−0.15–0.94)	1.000
51	12	8	3	296	6.3	4.7	0.97	0.52	0.67 (0.48–0.85)	0.227
52	17	7	4	291	7.5	6.6	0.97	0.61	0.74 (0.59–0.86)	0.549
53	10	2	0	307	3.8	3.1	0.99	0.83	0.91 (0.78–1.0)	0.500
54	3	3	4	309	1.9	2.2	0.98	0.30	0.45 (0.11–0.79)	1.000
56	8	3	0	308	3.4	2.5	0.99	0.73	0.84 (0.66–1.0)	0.250
58	7	1	1	310	2.5	2.5	0.99	0.78	0.87 (0.70–1.0)	1.000
59	5	3	1	310	2.5	1.9	0.99	0.56	0.71 (0.44–0.98)	0.625
66	13	5	2	299	5.6	4.7	0.98	0.65	0.78 (0.62–0.94)	0.453
68/73	7	5	5	302	3.8	3.8	0.97	0.41	0.57 (0.33–0.81)	1.000
70	7	4	0	308	3.4	2.2	0.99	0.64	0.77 (0.56–0.99)	0.125
74	7	1	2	309	2.5	2.8	0.99	0.70	0.82 (0.62–1.0)	1.000
UNCc	23	18	7	271	12.9	9.4	0.92	0.48	0.61 (0.46–0.75)	0.043

^aPC, PreservCyt, liquid-based medium; FTA, solid carrier device.

^bCalculated by using the exact McNemar χ² test.

^cUNC, uncharacterized, SPF10 positive but LiPA negative.